Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03111394 |
Other study ID # |
HS-16-00579 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
April 17, 2017 |
Est. completion date |
November 25, 2021 |
Study information
Verified date |
November 2021 |
Source |
University of Southern California |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
This is a pilot study looking at the feasibility of a mobile application (app) to collect
data from active tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), clinical magnetic
resonance imaging information and conduct genome-wide association studies in subjects with
multiple sclerosis. Participants will be self-referred to this study from different sources;
patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.
Description:
This is a pilot study evaluating the feasibility of a mobile application "myMS™" to collect
active clinical tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), magnetic resonance imaging
information and conduct genome-wide association studies in subjects with multiple sclerosis.
Participants will be self-referred to this study from different sources; patient advocacy
groups, social media tools, clinicaltrials.gov, and flyers.
Specific aims of this pilot study are:
1. To determine the feasibility and work flow in prospectively collecting surveys, clinical
tasks, magnetic resonance imaging (MRI) information for up to 200 self-referred adult MS
participants, using mobile app myMS™.
2. To determine the feasibility of using interface between myMS™ and 23andMe® DNA Kits and
23andme password protected mobile app platform (GSR Dashboard) in collecting one
biological (saliva) sample and distributing the genetic result (using commercially
available results only, distributed by 23andme®), for up to 200 self-referred adult MS
participants. This aim is for testing the system interface only. 23andme® has their own
independent consent form and IRB coverage for their commercial product.
3. To estimate the percentage of registered participants that will meet eligibility
criteria for MS.
4. To estimate the percentage of participants that a) complete all clinical tasks; b)
complete all surveys; c) provide genetic information; and d) provide MRI scans.